Clinical trials: B Cell
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)
Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or…
- Conditions
- Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- R/R (NCT04419389)
- Testing
- APR-246 (eprenetapopt) + Acalabrutinib in CLL, APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL, APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- Aprea Therapeutics
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Multiple Sclerosis, Relapsing-Remitting
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
B-cells have an important role in the pathogenesis of multiple sclerosis (MS). Ocrelizumab, a medication that targets B-cells have been found to be highly effective in stopping the disease activity in relapsing-remitting MS.
- Trial name
- NCT04261790
- Testing
- Ocrelizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
B-cell Lymphoma
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
This phase I clinical study was to investigate the safety, tolerability, and pharmacokinetics/pharmacodynamics of Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (BGB-3111) in Chinese participants with B-cell lymphoma by…
- Trial name
- NCT03189524
- Testing
- Zanubrutinib
- Where
- 4 sites in China
- Volunteers
- 44 people
- Sponsor
- BeiGene
Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response
Lymphoma is the 6th cancer in terms of incidence in France where approximately 11,000 new cases are diagnosed each year. Most types of lymphomas occur at all ages with a predominance in elderly subjects.
- Conditions
- Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Hodgkin
- Trial name
- NCT03154710
- Testing
- MOOVCARE
- Where
- 15 sites in France
- Volunteers
- 52 people
- Sponsor
- Weprom
Lymphoma
Reduced-Intensity Regimen Before Allogeneic Transplant for Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
RATIONALE: Photopheresis allows patient white blood cells to be treated with ultraviolet (UV) light and drugs outside the body to inactivate T cells.
- Trial name
- NCT00057954
- Testing
- Extracorporeal Photopheresis, Pentostatin, Total body irradiation (TBI)
- Where
- 19 sites in United States
- Volunteers
- 6 people
- Sponsor
- Eastern Cooperative Oncology Group
Primary Effusion Lymphoma, B-Cell Neoplasm
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Background: Primary effusion lymphoma (PEL) is a rare disease with no standard treatment. Researchers want to see if a drug called lenalidomide along with common chemotherapy drugs may be effective in treating PEL.
- Trial name
- NCT02911142
- Testing
- Lenalidomide, Rituximab, Prednisone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Large Cell, Diffuse
Chemotherapy for Participants With Lymphoma
The primary purpose of this study is to help answer the following research questions: To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin (R-GEMOX) can help participants with Diffuse Large B-Cell…
- Trial name
- NCT00436280
- Testing
- enzastaurin, gemcitabine, rituximab
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Leukemia, Lymphoma
Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide and fludarabine, total-body irradiation, and rituximab before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00387959
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Lymphoma
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00278161
- Testing
- Pegfilgrastim, Rituximab, Cyclophosphamide
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoma
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with…
- Trial name
- NCT00496873
- Testing
- Cytoxan, Nipent, Rituxan
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer…
- Trial name
- NCT00863369
- Testing
- rituximab, bortezomib, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- City of Hope Medical Center
Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
This phase II trial studies the side effects and how well bortezomib and vorinostat work in treating patients with non-Hodgkin lymphoma (NHL) after patients' own stem cell (autologous) transplant.
- Conditions
- Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00992446
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Bortezomib, Carmustine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Fred Hutchinson Cancer Center
Neoplasms
First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)
Arginine methylation mediated by protein arginine methyl-transferases (PRMTs) is an important post-translational modification of proteins involved in a diverse range of cellular processes.
- Trial name
- NCT03666988
- Testing
- GSK3368715
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 31 people
- Sponsor
- GlaxoSmithKline
B-Cell Chronic Lymphocytic Leukemia
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia.
- Trial name
- ORIGIN (NCT00910910)
- Testing
- Lenalidomide, Chlorambucil
- Where
- 165 sites in United States, Australia and 25 more
- Volunteers
- 450 people
- Sponsor
- Celgene
Mediastinal Large B-cell Lymphoma, Richter Syndrome
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)
In this study, participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter Syndrome (rrRS) will receive pembrolizumab (MK-3475).
- Trial name
- NCT02576990
- Testing
- Pembrolizumab
- Volunteers
- 80 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma, Large-Cell, Diffuse
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
- Trial name
- NCT00622388
- Testing
- Ofatumumab
- Where
- United Kingdom
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
This is a phase II study evaluating the safety, tolerability and efficacy of BKM120 in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL).
- Trial name
- NCT01693614
- Testing
- Buparlisib
- Where
- 20 sites in United States, Belgium and 6 more
- Volunteers
- 72 people
- Sponsor
- Novartis Pharmaceuticals
B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM
The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of ALXN6000 (samalizumab) in treating relapsing or refractory B-cell chronic lymphocytic leukemia (B-CLL) or multiple myeloma (MM) and to…
- Trial name
- NCT00648739
- Testing
- Samalizumab
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Relapsed/Refractory B-cell Malignancies
Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies
The primary objective of this study is to determine the long-term safety and tolerability of tirabrutinib in adults with relapsed/refractory B-cell malignancy who have tolerated and achieved stable disease or improved with…
- Trial name
- NCT02457559
- Testing
- Tirabrutinib
- Where
- 6 sites in France, United Kingdom
- Volunteers
- 29 people
- Sponsor
- Gilead Sciences